PLX4032: does it keep its promise for metastatic melanoma treatment?

PLX4032: does it keep its promise for metastatic melanoma treatment?

Item
http://www.wikidata.org/entity/Q37799845
Mutation of the BRAF genes in non-small cell lung cancerFunction and Clinical Implications of Long Non-Coding RNAs in Melanoma.Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandIn vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Towards new therapeutic approaches for malignant melanoma.Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma.Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.Equipoise should be amended, not abandoned.Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanomaAnticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.
P2860

PLX4032: does it keep its promise for metastatic melanoma treatment?

Item
http://www.wikidata.org/entity/Q37799845
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PLX4032: does it keep its promise for metastatic melanoma treatment?
@en
PLX4032: does it keep its promise for metastatic melanoma treatment?
@nl
type
label
PLX4032: does it keep its promise for metastatic melanoma treatment?
@en
PLX4032: does it keep its promise for metastatic melanoma treatment?
@nl
prefLabel
PLX4032: does it keep its promise for metastatic melanoma treatment?
@en
PLX4032: does it keep its promise for metastatic melanoma treatment?
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
PLX4032: does it keep its promise for metastatic melanoma treatment?
@en
P2093
P2860
P304
P31
P356
10.1517/13543784.2010.527945
P407
P433
P478
P50
P577
P5875
P698